275 filings
8-K
MBRX
Moleculin Biotech Inc
16 May 24
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress
8:32am
8-K
MBRX
Moleculin Biotech Inc
15 May 24
Regulation FD Disclosure
8:38am
8-K
MBRX
Moleculin Biotech Inc
14 May 24
Regulation FD Disclosure
4:16pm
8-K/A
MBRX
Moleculin Biotech Inc
13 May 24
Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update
10:53am
8-K
MBRX
Moleculin Biotech Inc
13 May 24
Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:30am
8-K
bovvgf5xqs r6
9 May 24
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
8:30am
8-K
ewe92logc 7afkp22
8 May 24
Regulation FD Disclosure
8:31am
8-K
15fquo8 t0xrgqjkt
7 May 24
Regulation FD Disclosure
4:13pm
8-K
yld 284cfhe02p0em0un
7 May 24
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
8:55am
8-K
9grkn1 4dkk
2 May 24
Regulation FD Disclosure
9:00am
8-K
ytffe1pbdu0 i2
25 Apr 24
Regulation FD Disclosure
8:23am
8-K
i6suqmu
18 Apr 24
Regulation FD Disclosure
8:30am
8-K
1r6h2d v8jr
10 Apr 24
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
8:30am
8-K
y2yf40fxrheam2nwk
8 Apr 24
Other Events
5:14pm
8-K
mgy4fmrx
27 Mar 24
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
9:05am
8-K
jvn k1i1gbafw5mxag
25 Mar 24
Regulation FD Disclosure
3:03pm
8-K
xho9nbztgqgqxn
25 Mar 24
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
7:30am
8-K
30o72v524hrbzwepji1w
22 Mar 24
Moleculin Reports Full Year 2023 Financial Results
4:08pm
8-K
z8z2e7irb xnvo3
20 Mar 24
Guidance to be provided for clinical development strategy for advancement of Annamycin into potential AML pivotal registration study
7:30am
8-K
q7q12f7
19 Mar 24
Moleculin Announces Reverse Stock Split
4:31pm